{"success":true,"data":{"pressRelease":{"id":"160353","rtpr_id":"nGNE3FdmMz-20261005","ticker":"PLRZ","exchange":"NASDAQ","all_tickers":["PLRZ"],"title":"Polyrizon Files for U.S. Patent Application to Expand IP Moat  Around Intranasal Drug-Delivery Platform","author":"Globe Newswire","published_at":"2026-10-05T11:32:00.207Z","article_body":"A new patent application covers Polyrizon’s proprietary mucoadhesive\nplatform and its potential applications in nasal drug delivery.\n\nRaanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) --  Polyrizon Ltd. (Nasdaq:\nPLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology\ncompany specializing in the development of innovative intranasal hydrogels,\ntoday announced that it has filed a new U.S. divisional patent application\nwith the United States Patent and Trademark Office (USPTO), further expanding\nthe Company’s intellectual property portfolio relating to its proprietary\nmucoadhesive technology.\n\nThe divisional application, titled “Mucoadhesive Polymers for Nasal Drug\nDelivery,” was assigned U.S. Patent Application No. 19/823,285.\n\nThe new application is part of Polyrizon’s broader patent family covering\nits proprietary mucoadhesive polymer technology. The technology is based on\npolymeric compositions designed for application to mucosal surfaces and\ncapable of forming a continuous and durable layer upon contact with mucosal\ntissue.\n\nThe underlying technology is designed to support a range of potential\napplications, including the use of mucoadhesive formulations as a platform for\nthe local or systemic delivery of therapeutic agents through mucosal tissues,\nincluding the nasal mucosa. The patent family describes the potential\nincorporation of therapeutic active ingredients into the mucoadhesive\ncompositions, providing a technological foundation for the development of\nintranasal drug delivery systems.\n\nThe divisional filing enables Polyrizon to pursue additional patent protection\nfor distinct aspects and applications of its technology while maintaining its\nconnection to the Company’s existing U.S. patent family.\n\nTomer Izraeli, Chief Executive Officer of Polyrizon, commented: “This new\nU.S. patent filing represents another step in strengthening the intellectual\nproperty foundation supporting our intranasal technology platform. We believe\nour mucoadhesive technology has potential beyond stand-alone barrier\napplications, particularly as a platform for delivering therapeutic agents\nthrough the nasal mucosa. Pursuing additional  patent protection for these\napplications is an important part of our strategy as we continue to explore\nthe broader potential of our technology.”\n\nPolyrizon continues to develop its proprietary mucoadhesive technology for\nboth stand-alone intranasal products and potential drug delivery applications.\nThe Company believes the ability of its platform to provide prolonged\ninteraction with mucosal surfaces may offer opportunities for the development\nof new approaches to local and systemic intranasal delivery.\n\nAbout Polyrizon\n\nPolyrizon is a development stage biotech company specializing in the\ndevelopment of innovative medical device hydrogels delivered in the form of\nnasal sprays, which form a thin hydrogel-based shield containment barrier in\nthe nasal cavity that can provide a barrier against viruses and allergens from\ncontacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and\nContain (TM), or C&C, hydrogel technology, comprised of a mixture of\nnaturally occurring building blocks, is delivered in the form of nasal sprays,\nand potentially functions as a “biological mask” with a thin shield\ncontainment barrier in the nasal cavity. Polyrizon are further developing\ncertain aspects of our C&C hydrogel technology such as the bioadhesion and\nprolonged retention at the nasal deposition site for intranasal delivery of\ndrugs. Polyrizon refers to its additional technology, which is in an earlier\nstage of pre-clinical development, that is focused on nasal delivery of active\npharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more\ninformation, please visit https://polyrizon-biotech.com.\n\nForward Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995 and other\nsecurities laws. Words such as “expects,” “anticipates,”\n“intends,” “plans,” “believes,” “seeks,” “estimates” and\nsimilar expressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the potential applications of its mucoadhesive\ntechnology, including as a platform for the local or systemic delivery of\ntherapeutic agents through mucosal tissues; the potential benefits and\nopportunities associated with prolonged interaction with mucosal surfaces; the\nCompany’s ability to obtain additional patent protection for its technology;\nand the Company’s plans to continue developing and exploring applications of\nits technology. The Company cannot assure that any patent will issue as a\nresult of a pending patent application or, if issued, whether it will issue in\na form that will be advantageous to the Company. Forward-looking statements\nare not historical facts, and are based upon management’s current\nexpectations, beliefs and projections, many of which, by their nature, are\ninherently uncertain. Such expectations, beliefs and projections are expressed\nin good faith. However, there can be no assurance that management’s\nexpectations, beliefs and projections will be achieved, and actual results may\ndiffer materially from what is expressed in or indicated by the\nforward-looking statements. Forward-looking statements are subject to risks\nand uncertainties that could cause actual performance or results to differ\nmaterially from those expressed in the forward-looking statements. For a more\ndetailed description of the risks and uncertainties affecting the Company,\nreference is made to the Company’s reports filed from time to time with the\nSecurities and Exchange Commission (“SEC”), including, but not limited to,\nthe risks detailed in the Company’s Annual Report on Form 20-F for the\nfiscal year ended December 31, 2025 and subsequent filings with the SEC.\nForward-looking statements speak only as of the date the statements are made.\nThe Company assumes no obligation to update forward-looking statements to\nreflect actual results, subsequent events or circumstances, changes in\nassumptions or changes in other factors affecting forward-looking information\nexcept to the extent required by applicable securities laws. If the Company\ndoes update one or more forward-looking statements, no inference should be\ndrawn that the Company will make additional updates with respect thereto or\nwith respect to other forward-looking statements. References and links to\nwebsites have been provided as a convenience, and the information contained on\nsuch websites is not incorporated by reference into this press release.\nPolyrizon is not responsible for the contents of third-party websites.\n\nContacts:\n\nMichal Efraty\nInvestor Relations\nIR@polyrizon-biotech.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE3FdmMz-20261005","title":"Polyrizon Files for U.S. Patent Application to Expand IP Moat  Around Intranasal Drug-Delivery Platform","author":"Globe Newswire","ticker":"PLRZ","created":"2026-10-05T11:32:00.207Z","tickers":["PLRZ"],"exchange":"NASDAQ","article_body":"A new patent application covers Polyrizon’s proprietary mucoadhesive\nplatform and its potential applications in nasal drug delivery.\n\nRaanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) --  Polyrizon Ltd. (Nasdaq:\nPLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology\ncompany specializing in the development of innovative intranasal hydrogels,\ntoday announced that it has filed a new U.S. divisional patent application\nwith the United States Patent and Trademark Office (USPTO), further expanding\nthe Company’s intellectual property portfolio relating to its proprietary\nmucoadhesive technology.\n\nThe divisional application, titled “Mucoadhesive Polymers for Nasal Drug\nDelivery,” was assigned U.S. Patent Application No. 19/823,285.\n\nThe new application is part of Polyrizon’s broader patent family covering\nits proprietary mucoadhesive polymer technology. The technology is based on\npolymeric compositions designed for application to mucosal surfaces and\ncapable of forming a continuous and durable layer upon contact with mucosal\ntissue.\n\nThe underlying technology is designed to support a range of potential\napplications, including the use of mucoadhesive formulations as a platform for\nthe local or systemic delivery of therapeutic agents through mucosal tissues,\nincluding the nasal mucosa. The patent family describes the potential\nincorporation of therapeutic active ingredients into the mucoadhesive\ncompositions, providing a technological foundation for the development of\nintranasal drug delivery systems.\n\nThe divisional filing enables Polyrizon to pursue additional patent protection\nfor distinct aspects and applications of its technology while maintaining its\nconnection to the Company’s existing U.S. patent family.\n\nTomer Izraeli, Chief Executive Officer of Polyrizon, commented: “This new\nU.S. patent filing represents another step in strengthening the intellectual\nproperty foundation supporting our intranasal technology platform. We believe\nour mucoadhesive technology has potential beyond stand-alone barrier\napplications, particularly as a platform for delivering therapeutic agents\nthrough the nasal mucosa. Pursuing additional  patent protection for these\napplications is an important part of our strategy as we continue to explore\nthe broader potential of our technology.”\n\nPolyrizon continues to develop its proprietary mucoadhesive technology for\nboth stand-alone intranasal products and potential drug delivery applications.\nThe Company believes the ability of its platform to provide prolonged\ninteraction with mucosal surfaces may offer opportunities for the development\nof new approaches to local and systemic intranasal delivery.\n\nAbout Polyrizon\n\nPolyrizon is a development stage biotech company specializing in the\ndevelopment of innovative medical device hydrogels delivered in the form of\nnasal sprays, which form a thin hydrogel-based shield containment barrier in\nthe nasal cavity that can provide a barrier against viruses and allergens from\ncontacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and\nContain (TM), or C&C, hydrogel technology, comprised of a mixture of\nnaturally occurring building blocks, is delivered in the form of nasal sprays,\nand potentially functions as a “biological mask” with a thin shield\ncontainment barrier in the nasal cavity. Polyrizon are further developing\ncertain aspects of our C&C hydrogel technology such as the bioadhesion and\nprolonged retention at the nasal deposition site for intranasal delivery of\ndrugs. Polyrizon refers to its additional technology, which is in an earlier\nstage of pre-clinical development, that is focused on nasal delivery of active\npharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more\ninformation, please visit https://polyrizon-biotech.com.\n\nForward Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995 and other\nsecurities laws. Words such as “expects,” “anticipates,”\n“intends,” “plans,” “believes,” “seeks,” “estimates” and\nsimilar expressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the potential applications of its mucoadhesive\ntechnology, including as a platform for the local or systemic delivery of\ntherapeutic agents through mucosal tissues; the potential benefits and\nopportunities associated with prolonged interaction with mucosal surfaces; the\nCompany’s ability to obtain additional patent protection for its technology;\nand the Company’s plans to continue developing and exploring applications of\nits technology. The Company cannot assure that any patent will issue as a\nresult of a pending patent application or, if issued, whether it will issue in\na form that will be advantageous to the Company. Forward-looking statements\nare not historical facts, and are based upon management’s current\nexpectations, beliefs and projections, many of which, by their nature, are\ninherently uncertain. Such expectations, beliefs and projections are expressed\nin good faith. However, there can be no assurance that management’s\nexpectations, beliefs and projections will be achieved, and actual results may\ndiffer materially from what is expressed in or indicated by the\nforward-looking statements. Forward-looking statements are subject to risks\nand uncertainties that could cause actual performance or results to differ\nmaterially from those expressed in the forward-looking statements. For a more\ndetailed description of the risks and uncertainties affecting the Company,\nreference is made to the Company’s reports filed from time to time with the\nSecurities and Exchange Commission (“SEC”), including, but not limited to,\nthe risks detailed in the Company’s Annual Report on Form 20-F for the\nfiscal year ended December 31, 2025 and subsequent filings with the SEC.\nForward-looking statements speak only as of the date the statements are made.\nThe Company assumes no obligation to update forward-looking statements to\nreflect actual results, subsequent events or circumstances, changes in\nassumptions or changes in other factors affecting forward-looking information\nexcept to the extent required by applicable securities laws. If the Company\ndoes update one or more forward-looking statements, no inference should be\ndrawn that the Company will make additional updates with respect thereto or\nwith respect to other forward-looking statements. References and links to\nwebsites have been provided as a convenience, and the information contained on\nsuch websites is not incorporated by reference into this press release.\nPolyrizon is not responsible for the contents of third-party websites.\n\nContacts:\n\nMichal Efraty\nInvestor Relations\nIR@polyrizon-biotech.com"},"type":"article","timestamp":"2026-10-05T11:32:00.300626432Z","server_sent_at_ms":1791199920300},"received_at":"2026-10-05T11:32:00.350Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}